Monitoring humoral and cellular immunity over 6 months after mRNA-based bivalent COVID-19 vaccine administration  

作　　者：Laura Pighi Brandon MHenry Simone De Nitto Gian Luca Salvagno Giuseppe Lippi 

机构地区：[1]Section of Clinical Biochemistry,University of Verona,Verona,Italy [2]Service of Laboratory Medicine,Pederzoli Hospital,Peschiera del Garda,Italy [3]Clinical Laboratory,Division of Nephrology and Hypertension,Cincinnati Children’s Hospital Medical Center,Cincinnati,OH,USA

出　　处：《Infectious Diseases Research》2023年第4期22-23,共2页传染病研究（英文）

摘　　要：Dear Editor,Although the World Health Organization(WHO)has declared an end to the global emergency for coronavirus disease 2019(COVID-19)[1],the clinical burden of severe acute respiratory syndrome coronavirus disease(SARS-CoV-2)has not yet subsided[2,3],especially after the emergence of new variants such as EG.5 and BA.2.86,whose genetic leap is so large that it may contribute to increase the number of new COVID-19 cases,hospitalizations,and deaths[3].Some physical preventive measures,such as mask-wearing,hand hygiene,and isolation of positive cases,play an important role.However,widespread vaccination remains the cornerstone to contain the spread of the virus and mitigate the potential harm to human health.

关 键 词：immunity acute sided 

分 类 号：R37[医药卫生—病原生物学]